Acea Biosciences, Inc.

Aviva Biosciences Corporation

Agilent Technologies, Inc.

Acea Therapeutics, Inc.

Tsinghua University

Roche Diagnostics Operations, Inc.

Captialbio Corporation

Hangzhou Acea Pharmaceutical Research Co., Ltd.

Zhejiang Acea Pharmaceuticals Co., Ltd.

Xiaobo Wang

Xiao Xu

Yama A Abassi

Biao Xi

Nan Li

Lei Wu

Junquan Xu

Jing Cheng

Long Mao

Li Zhao

Mingxian Huang

Guoliang Tao

Jian Wu

Weiping Yang

Jia Xu

Josephine Atienza

Wen Fu Zhang

Tianxing Wang

Ye Chen

Douglas T Yamanishi

George T Walker

David M Rothwarf

Jiangbo Gan

Joe Ouyang

Naichen Yu

Paul G Hujsak

Haoyun An

Litian Liu

Ning Ke

Sara F Snyder

Xiaoyu Zhang

Ping Lin

Wei Ouyang

Guo Liang Tao

Charina Schmitigal

Wei Li

Hyunsun Chung

Manfred Watzele

Depu Chen

Wei Shao

Jia Liu

Xin Yao

Alexander Seiler

Yuning Hua

Bojie Weng

Baoquan Sun

Yimei Bao

Yile Chen

Kongen Dai

Qiting Ye

Longbin Fang

Wanhong Xu

Donald Thomas

Lingbo Kong

Zengqiang Li

Yama Abassi

Guoqing Wang

Yuxiang Zhou

Xiaopeng Mo

Sean Lee

Antonio Guia

Lincoln Muir

Brandon Lamarche

Ming Xiang Huang

Caixia Yang

Jun Quan Xu

Zhi Tao

Zhaohuai Yang

Mingxiang Huang

Elizabeth Kwok

Adrian Papas

Kilo Vilayphone

Yangde Qin

Ting Cheng

Xi-aopeng Mo

Jing Tsinghua University Cheng

Methods of assessing cytolysis of cancer cells are provided, which include: providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, adding target cells characterized as cancer cells to a well of the device adding effector cells to the well to form a test well, where the effector cells are immune cells obtained or derived from a same patient as the target cells; monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the impedance; and determining effectiveness of effector cell killing of the target cells by comparing the impedance or impedance-based curves over time.

Cell-substrate impedance monitoring of cancer cells

A system for electronically and optically monitoring biological samples, the system including: a multi-well plate having a plurality of wells configured to receive a plurality of biological samples, each of the wells having a set of electrodes and a transparent window on a bottom surface of the well that is free of electrodes; an illumination module configured to illuminate the wells; a cradle configured to receive the multi-well plate, the cradle having an opening on the bottom that exposes the transparent windows of the wells; and an optical imaging module movable across different wells of a same multi-well plate to capture images through the windows.

Systems and methods for electronically and optically monitoring biological samples

A system for monitoring cells, which includes a device for monitoring cell-substrate impedance, the device having a plurality of wells on a nonconductive substrate, where each of the plurality of wells has an electrode array fabricated on the substrate for measurement of cell-substrate impedance; an impedance analyzer that measures cell-substrate impedance from the plurality of wells; electronic circuitry with multiple analogue-to-digital conversion channels, where the electronic circuitry electrically connects the electrode arrays to the impedance analyzer such that the electrode arrays are electrically monitored at millisecond time resolution; and a software program that analyzes the measured cell-substrate impedance.

Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution

Methods of inducing functional maturation of immature cardiomyocytes derived from induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) by electrically pacing the immature cardiomyocytes according to a pulse profile that induces maturation until the immature cardiomyocytes mature into functionally adult cardiomyocytes.

Methods and systems for functional maturation of iPSC and ESC derived cardiomyocytes

The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Heterocyclic compounds and uses as anticancer agents

Methods for identifying compounds that modulate cellular responses stimulated by IgE, which include providing an impedance-based system that monitors cell-substrate impedance of cells on a substrate; introducing cells to the substrate of the system; adding at least one test compound and IgE to the cells, wherein the at least one test compound is suspected of modulating cell responses stimulated by the IgE; adding an antigen to the cells; monitoring the cell-substrate impedance of cells on the substrate; and analyzing the cell-substrate impedance to evaluate whether the at least one test compound alters a cellular response to stimulation with the IgE.

Real time electronic cell sensing systems and applications for cell-based assays

The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions. 

Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide

A system for monitoring cell-substrate impedance of excitable cells at millisecond time resolution and methods of assessing cell beating by monitoring cell-substrate impedance of beating cells at millisecond time resolution.

Devices, systems and methods for monitoring excitable cells, such as cardiomyocytes, on microelectrode arrays that couple the electro-stimulation of excitable cells to induce or regulate cardiomyocyte beating and the simultaneous measurement of impedance and extracellular recording to assess changes in cardiomyocyte beating, viability, morphology or electrophysical properties in response to a plurality of treatments.

System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties

A system for detecting signal components of light induced by multiple excitation sources including: a flow channel including at least two spatially separated optical interrogation zones; a non-modulating excitation source that directs a light beam of a first wavelength at a near constant intensity onto a first of the optical interrogation zones; a modulating excitation source that directs a light beam of a second wavelength with an intensity modulated over time at a modulating frequency onto a second of the optical interrogation zones; a detector subsystem comprising a set of detectors configured to detect light emitted from particles flowing through the at least two optical interrogation zones and to convert the detected light into a total electrical signal; and a processor that determines signal components from the light detected from each of the optical interrogation zones.

System and method for detecting multiple-excitation-induced light in a flow channel

Instrument for analyzing biological cells

The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

EGFR modulators and uses thereof

A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.

Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer

Growing community of inventors

San Diego, CA, United States of America

Xiaobo Wang